Evidence map›Paper›PMID 41521280›Full record

ArticleAnnals of biomedical engineering2026

Systemic Treatments Impact Bone Quality in a Preclinical Model of Mixed Femoral Metastases.

Azin Mirzajavadkhan, Leanna E Abraham, Margarete K Akens, Michael Hardisty, Cari M Whyne

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Azin MirzajavadkhanFaculty of Engineering, Institute of Biomedical Engineering, University of Toronto, 164 College Street, Toronto, ON, M5S 3G9, Canada.ORCID http://orcid.org/0000-0002-6100-0237
Leanna E AbrahamPhysical Sciences Platform and Holland Bone and Joint Program, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada.ORCID http://orcid.org/0000-0003-4610-000X
Margarete K AkensDepartment of Medical Biophysics, University of Toronto, 101 College Street, Toronto, ON, M5G 1L7, Canada.ORCID http://orcid.org/0000-0003-3523-2381
Michael HardistyFaculty of Engineering, Institute of Biomedical Engineering, University of Toronto, 164 College Street, Toronto, ON, M5S 3G9, Canada.ORCID http://orcid.org/0000-0002-8941-3543
Cari M WhyneFaculty of Engineering, Institute of Biomedical Engineering, University of Toronto, 164 College Street, Toronto, ON, M5S 3G9, Canada. cari.whyne@sunnybrook.ca.ORCID http://orcid.org/0000-0002-6822-8314

Funding

CIHR 156175CIHR 180337
6 · The paper itself

Abstract

Skeletal metastases disrupt bone remodeling, compromising mechanical integrity and increasing fracture risk. Cancer therapies can further influence bone quality. This study aimed to evaluate the impact of systemic cancer therapies (docetaxel (DTX) and zoledronic acid (ZA)) on bone quality in a preclinical model of mixed femoral metastases. Mixed metastases were induced in 5-6-week-old athymic male rats via intracardiac injection of luciferase-transfected ACE-1 canine prostate cancer cells (day 0). Healthy and inoculated rats were randomly assigned to receive no treatment, DTX (5 mg/kg), or ZA (60 μg/kg) on day 10. Tumor development was confirmed with bioluminescence imaging (day 14 and 21). Animals were euthanized on day 21. Bilateral femora were excised and underwent μCT scanning. Trabecular bone in the left femora was segmented for microstructural analysis. The left distal femora were then cut to 1 cm length and stained with barium sulfate for high-resolution μCT imaging to assess microdamage. The cut femora were then loaded to failure under axial compression. The right femora were processed for histology to evaluate bone histoarchitecture and verify tumor presence. DTX, despite lower bone mineral density, bone volume fraction, and trabecular number, showed reduced microdamage accumulation and improved load to failure in inoculated animals. ZA improved microstructural parameters, reduced damage volume fraction, and enhanced load to failure compared to inoculated untreated animals. These findings highlight the differential impact of cancer therapies on the quality of healthy and metastatic bone. Understanding these effects is essential for optimizing treatment strategies and minimizing skeletal complications secondary to skeletal metastases.

Indexed as

Antineoplastic AgentsDiphosphonatesFemoral NeoplasmsFemurImidazolesProstatic NeoplasmsTaxoidsAnimalsBone DensityCell Line, TumorDocetaxelDogsMaleRatsRats, NudeZoledronic AcidAntineoplastic AgentsDiphosphonatesDocetaxelImidazolesTaxoidsZoledronic AcidBone qualityDocetaxelLoad to failureMicrodamageSkeletal metastasesZoledronic acid

Identifiers

PMID41521280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.